Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study

Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study

Adolescents can develop a severe form of Coronavirus disease 2019 (COVID-19), especially with underlying comorbidities. No study has examined the efficacy or effectiveness of inactivated COVID-19 vaccines in adolescents. This single-center, prospective cohort study was performed to evaluate the safe...

Full description

Bibliographic Details
Main Authors: Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Preeda Vanichsetakul, Saraiorn Thonginnetra, Krongkwan Niemsorn, Pathariya Promsena, Manunya Tandhansakul, Naruporn Kasemlawan, Natthanan Ruangkijpaisal, Narin Banomyong, Nanthida Phattraprayoon, Teerapat Ungtrakul, Kasiruck Wittayasak, Nawarat Thonwirak, Kamonwan Soonklang, Gaidganok Sornsamdang, Nithi Mahanonda
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Vaccines
Subjects:
COVID-19
SARS-CoV-2
adolescent
BBIBP-CorV
safety
immunogenicity
Online Access:https://www.mdpi.com/2076-393X/10/5/807

Internet

https://www.mdpi.com/2076-393X/10/5/807

Similar Items